<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2795">
  <stage>Registered</stage>
  <submitdate>28/05/2010</submitdate>
  <approvaldate>28/05/2010</approvaldate>
  <nctid>NCT01134562</nctid>
  <trial_identification>
    <studytitle>Safety, Tolerability and Pharmacokinetics of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism</studytitle>
    <scientifictitle>A Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Study to Assess the Safety and Tolerability of Single Ascending Doses of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>KAI-4169-002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hyperparathyroidism, Secondary</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other endocrine disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Saline
Treatment: drugs - KAI-4169

Placebo Comparator: Placebo - Subjects will be randomly assigned to receive either KAI-4169 or placebo

Experimental: KAI-4169 - Subjects will be randomly assigned to receive either KAI-4169 or placebo


Treatment: drugs: Saline
Single IV injection

Treatment: drugs: KAI-4169
Single IV injection

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and tolerability of rising single doses of KAI-4169 by IV injection in hemodialysis subjects with secondary hyperparathyroidism</outcome>
      <timepoint>3 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Assess the effect of KAI-4169 on iPTH and serum calcium</outcome>
      <timepoint>3 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics of rising single doses of KAI-4169 by IV injection in hemodialysis subjects with secondary hyperparathyroidism</outcome>
      <timepoint>3 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subjects provides written informed consent.

          -  iPTH at least 300 pg/mL (32 pmol/L) and no greater than 1200 pg/mL (127 pmol/L) and
             corrected calcium at least 9.0 mg/dL (2.25 mmol/L)

          -  Adequate hemodialysis three times per week

          -  Excepting chronic renal failure, subject is judged to be in stable medical condition
             based on medical history, physical examination, and routine laboratory tests</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History or symptomatic ventricular dysrhythmias

          -  History of angina pectoris or congestive heart failure

          -  History of myocardial infarction, coronary angioplasty, or coronary artery bypass
             grafting within the past 6 months

          -  History of or treatment for seizure disorder

          -  Recent (3 months) parathyroidectomy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>16</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,VIC</recruitmentstate>
    <hospital> - Brisbane</hospital>
    <hospital> - Melbourne</hospital>
    <postcode> - Brisbane</postcode>
    <postcode> - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>KAI Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to characterize the safety and tolerability of single rising
      doses of KAI-4169 in hemodialysis subjects with secondary hyperparathyroidism.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01134562</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gregory Bell, MD</name>
      <address>KAI Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>